
Diagnocure, Inc. Share · CA2519121016 (OTC) Canada · Healthcare — real-time prices and quotes, company data, dividends, fundamentals, and AI-powered portfolio analysis on MoneyPeak
AI-Powered Analysis
Fundamental Analysis
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of Diagnocure, Inc.
No Price
Company Profile for Diagnocure, Inc. Share
Diagnocure, Inc., a life sciences company, develops and commercializes products relating to the diagnosis of cancer in Canada. It focuses on molecular diagnostic tests for the detection and management of cancer. The company offers PCA3 test for the diagnosis of prostate cancer; and Guanylyl Cyclase C (GCC) marker and Previstage GCC colorectal cancer staging test for colorectal cancer patients, as well as PCP, a multi marker prostate cancer test. It also provides gene expression and copy number variation analysis, mutation detection, SNP genotyping, and platform and laboratory environmental services. The company was formerly known as DiagnoCure Inc. 9342-8530 Québec Inc. was founded in 1994 and is headquartered in Quebec, Canada.
Company Data
Name Diagnocure, Inc.
Company Diagnocure, Inc.
Website
https://www.diagnocure.com
Primary Exchange
UTC
ISIN CA2519121016
Asset Class Share
Sector Healthcare
Industry Medical - Specialties
CEO Yves Fradet F.R.C.S.,
Country Canada
Currency USD
Employees 0,0 T
Address 4535 Wilfrid-Hamel Boulevard, G1P 2J7 Quebec
IPO Date 2009-09-08
Dividends from 'Diagnocure, Inc.'
| Ex-Date | Dividend per Share |
|---|---|
| 14.03.2016 | 0,12 USD |
| 24.02.2016 | 0,12 USD |
Ticker Symbols
| Name | Symbol |
|---|---|
| Over The Counter | DGCRF |